1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Market Spotlight: Hypogonadism

Market Spotlight: Hypogonadism

  • November 2019
  • 36 pages
  • ID: 5780044
  • Format: PDF
  • By Pharma Intelligence


Table of Contents

This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
The largest proportion of industry-sponsored drugs in active clinical development for hypogonadism are in Phase II, with only one drug in the NDA/BLA phase.
Therapies in development for hypogonadism focus on targets such as androgen receptors, estrogen receptor alpha, estrogen receptor beta, gonadotropin-releasing hormone, and aromatase. The majority of the pipeline drugs are administered via the oral route, with the remainder being subcutaneous and transdermal formulations.
An expected PDUFA date for Tlando is the only high-impact upcoming event in the hypogonadism space. The overall likelihood of approval of a Phase I endocrine-other asset is 23.6%, and the average probability a drug advances from Phase III is 77.4%. Drugs, on average, take 9.2 years from Phase I to approval, compared to 9.1 years in the overall endocrine space.
There have been 16 licensing and asset acquisition deals involving hypogonadism drugs during 2014–19. The $317.5m exclusive license agreement signed in 2014 between Apricus and Forendo for fispemifene, an investigational treatment for urological conditions in men, was the largest deal.
The distribution of clinical trials across Phase I–IV indicates that trials for hypogonadism have been evenly split between the early and late phases of development, with 51% of trials in Phase I–II and 49% in Phase III–IV.
The US has a substantial lead in the number of hypogonadism clinical trials globally. The UK leads the major EU markets, while India has the top spot in Asia.
Clinical trial activity in the hypogonadism space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for hypogonadism, with eight trials.
AbbVie leads industry sponsors with the highest overall number of clinical trials for hypogonadism, followed by GlaxoSmithKline

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2019

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, ...

5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2019

5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2019Summary5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 10 molecules. Out of which ...

Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019

Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, ...

Anti-Tumor Drugs Markets in China $ 4000 October 2019


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on